{"id":125450,"date":"2021-05-18T07:17:41","date_gmt":"2021-05-18T07:17:41","guid":{"rendered":"https:\/\/precoinnews.com\/?p=125450"},"modified":"2021-05-18T07:17:41","modified_gmt":"2021-05-18T07:17:41","slug":"vaccine-candidate-from-canadas-medicago-shows-strong-antibody-response-to-covid-19","status":"publish","type":"post","link":"https:\/\/precoinnews.com\/markets\/vaccine-candidate-from-canadas-medicago-shows-strong-antibody-response-to-covid-19\/","title":{"rendered":"Vaccine candidate from Canada's Medicago shows strong antibody response to COVID-19"},"content":{"rendered":"
(Reuters) – Canadian drug developer Medicago\u2019s plant-based COVID-19 vaccine candidate, which is enhanced by a GlaxoSmithKline treatment, was able to create a strong antibody response in a mid-stage study, the two companies said on Tuesday.<\/p>\n
The vaccine produced a neutralizing response that was about 10 times higher than in people recovering from COVID-19.<\/p>\n
After two doses, the vaccine candidate induced robust immune responses in all the trial participants irrespective of age and no safety concerns or adverse events were reported, the companies said.<\/p>\n
Medicago, which has Canada\u2019s most advanced COVID-19 vaccine project under development, had in March started a late-stage study of the refrigerator-stable candidate in 30,000 participants in North America, Latin America and Europe.<\/p>\n
The Medicago vaccine uses a technology known as virus-like particles, which mimic the structure of the coronavirus, but do not contain genetic material from it.<\/p>\n